Shares of Revance Therapeutics (NASDAQ: RVNC) are under pressure after management announced the pricing of a secondary offering. Investors dismayed by the pricing of the offering have hammered the biotech stock 16.4% lower as of 12:07 p.m. EST on Wednesday.
Revance shares had been climbing since the company submitted an application to the FDA for DAXI late last month. On Monday, shares of Revance peaked above $20 per share and stayed there through the end of Tuesday's session, which is why investors were surprised at the $17 per share offering price announced today.
Image source: Getty Images.
DAXI is a longer-lasting version of the world's favorite neurotoxin, Botox, and Revance has evidence to prove it works better. That means Revance could end up competing with AbbVie (NYSE: ABBV) for a slice of Botox sales, which have risen to around $2.7 billion annually.
Within a couple of months, we'll know if the FDA will begin a review of DAXI that will probably last 10 months. Revance's collaboration partner, Mylan (NASDAQ: MYL), passed on the chance to fund late-stage development of DAXI in August and has until April 30, 2020, to change its mind.
If Mylan agrees to launch DAXI and give Revance a mid-double-digit royalty percentage on future sales, it could get much harder for AbbVie's acquisition of Allergan to deliver a positive return.
10 stocks we like better than Revance Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Revance Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 1, 2019
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.